Aksys Ltd (CE) (AKSY) 시세

AKSY SEC Suspension:

http://www.sec.gov/litigation/suspensions/2014/34-71465.pdf

Order:

http://www.sec.gov/litigation/suspensions/2014/34-71465-o.pdf

AKSY Shares Outstanding 32,446,084 a/o Nov 01, 2006

AKSY http://www.otcmarkets.com/stock/AKSY/filings http://www.linkedin.com/company/aksys-ltd.
http://www.onemedplace.com/database/list/cid/492/

AKSY historical: http://www.profitspi.com/stock/view.aspx?v=price-and-chart&p=965&i=AKSY&pv=recent-symbols&pp=AKSY#&&vs=634998364998591520

AKSY .005 http://investorshub.advfn.com/boards/msgsearch.aspx?searchstr=aksy

Playing this one off disparate volume, and recent move up 'combined'.

JMO

AKSY .001 very active lately, on-watch: http://www.profitspi.com/stock/view.aspx?v=price-and-chart&p=965&i=AKSY&pv=recent-symbols&pp=AKSY#&&vs=634957458241714042

The value of volume data can be:

Individual 10Day Average
Grouped volume days compared to
PPS high rolling into a PPS low, then individual/grouped
Flowing data indicators

sc

Follow me on twitter. http://www.twitter.com/penniespastor

this was just a play. something big coming. keep on your radar. We should be able to play it again. I will add on the dip

That didn't work out too well.. Care to update the sticky?

Thanks for the info

I called that number yesterday and they deny that there is any affiliation with AKSY.
There is no link to PDC, it is an entirely different corporation.

Domain name: aksys.com

Registrant Contact:
Physical Dynamics Corporation
R. Wilcox
+1.8584541400
Fax: +1.8584541300
7825 Fay Avenue Suite 200
La Jolla, CA 92037US

Dialysis machine firm Aksys shuts down

Feb. 20, 2007 — Aksys Ltd., the Lincolnshire-based maker of home-based kidney dialysis machines, has pulled the plug.

The 16-year-old company’s board of directors last month voted to shut down operations after trying for months to sell its assets or attract outside financing. In a filing with the Securities and Exchange Commission on Tuesday, Aksys said it owes $23.4 million on a loan from its majority shareholder, Durus Life Sciences Master Fund Ltd.

Durus, a hedge fund, had told Aksys it would not continue to fund the company without additional financing from a third party. Aksys lost $24.5 million during the first nine months of 2006, according to its last quarterly financial statement.

In 2003, Durus said it had become a controlling investor by “inadvertently” purchasing more than 70% of Aksys’ outstanding shares over the previous year, but had not disclosed the purchases as required by SEC rules.

Aksys shares declined steadily after that disclosure amid investor concern that the share price would crater if Durus dumped its stake.

Aksys sued Durus in August 2003, seeking an injunction and damages for what it alleged were securities violations for not disclosing that it had acquired large amounts of Aksys shares.

Durus eventually agreed to pay Aksys nearly $50 million and slowly sell its shares, a process that was expected to take a decade. Durus still owned 66% of Aksys’ outstanding shares as of December, when its stock was delisted from Nasdaq after failing to stay above the $35-million market-capitalization threshold.

Durus founder Scott Sacane last month was sentenced to three years in prison after pleading guilty to charges that he manipulated the shares of Aksys and another small biotechnology company, Esperion Therapeutics Inc.

A phone message left at Aksys’ headquarters Tuesday was not immediately returned. Its Web site was inactive.

A number for Durus Capital Management in Norwalk, Conn., is disconnected

http://www.chicagobusiness.com/cgi-bin/news.pl?id=23931

Industry : Medical Instruments & Supplies
Employees : 87
Exchange : Other OTC Issues

Aksys, Ltd. (Aksys) was established to provide hemodialysis products and services for patients suffering from end-stage renal disease (ESRD), commonly known as chronic kidney failure. The Company has developed an automated personal hemodialysis system, known as the Aksys Personal Hemodialysis (PHD) System (the PHD System), which is designed to enable patients to perform frequent hemodialysis at alternate sites (such as their own homes), and to thereby improve clinical outcomes, reduce total ESRD treatment costs and enhance the quality of life of patients. The Company’s target market is the ESRD treatment market. A healthy human kidney continuously removes waste products and excess water from the blood. ESRD is a slow, progressive loss of kidney function caused by inherited disorders, prolonged medical conditions, such as diabetes and hypertension, or the long-term use of certain medications. ESRD is irreversible and lethal if untreated.

This company ceased operations in 2007. It's assets were foreclosed on and sold off.

On March 28, 2007, the board of directors of Aksys Ltd., a Delaware corporation (the “Company”), authorized an assignment for the benefit of creditors. An assignment for the benefit of creditors is designed to allow for an orderly winding up of any remaining assets and liabilities of the Company by the appointment of a third party assignee experienced with winding up businesses and settling liability claims.
As previously reported, the Company has ceased active operations and most of its remaining assets have been sold or foreclosed upon. On March 9, 2006, Durus Life Sciences Master Fund Ltd. (the “Secured Creditor”) closed a private foreclosure sale pursuant to which the Secured Creditor sold substantially all of the property subject to the security interest under the security agreement dated as of June 23, 2006, by and between the Company and the Secured Creditor
On March 29, 2007, the Company also filed a Form 15 with the Securities and Exchange Commission seeking deregistration of its securities under the Securities Exchange Act of 1934, as amended. The Company believes that it no longer has the requisite number of holders of record required to continue its reporting obligations.
Given the amount of the Company’s remaining liabilities, the Company does not anticipate any distributions for its stockholders from its remaining assets.

http://www.sec.gov/Archives/edgar/data/902600/000095013707005248/c13902e8vk.htm

Whats the deal here? Why the huge gain today?

we should see 5000% on AKSY tomorrow. This is just the beginning.